Effect Of Neoadjuvant Chemotherapy On Stromal CD10 Antigens In Breast Cancer

BackgroundThe incidence of breast cancer in China showed a slow upward trend in the past 50years,it has been ranked first in female cancer.Breast cancer usually occurs in women aged 40-60,the pathogenesis is not fully understood,long-term effects of estrogen,familial genetic predisposition,environmental factors,and prolonged high-dose radiation exposure connect with breast cancer pathogenesis.With the social development,breast cancer treatment from single surgery turn into surgery,chemotherapy,radiation therapy,targeted therapy and hormone therapy combination of comprehensive treatment and individualized treatment modalities.Neoadjuvant chemotherapy which is a form of chemotherapy,from the 1970s began to use,it has been accepted by the majority of patients.Clinical studies have shown:neoadjuvant chemotherapy to reduce tumor stage,increased opportunities for advanced breast cancer surgery and breast conservation opportunities,but can also evaluate chemosensitivity,timely replacement of chemotherapy drugs.However,according to current data suggest that neoadjuvant chemotherapy response rate was 60%-90%,which means 10%-35%of patients may appear insensitive to chemotherapy drugs in neoadjuvant chemotherapy.They delay surgery and other effective treatment time.Therefore,to predict neoadjuvant chemotherapy effect is very important,explore predictors of neoadjuvant chemotherapy can advance to select the appropriate individualized treatment plan for patients,relieve pain ineffective chemotherapy.Until now some researches on CD10 in breast cancer,most of them mainly focus on CD10 expression in breast cancer connect with lymph node metastasis,recurrence and survival rate of correlation,but the relation-ship between the expression of CD10 and the evaluation of the neoadjuvant chemotherapy is very poor.Purpose1.Analyze the differences between CD10 expression and changes of neoadjuvant chemotherapy before and after,to explore the impact of neoadjuvant chemotherapy on the expression of CD10;2.Exploration the relationship between expression of CD10 and neoadjuvant chemotherapy,assuming CD10 efficacy of neoadjuvant chemotherapy as a predictor can be set up;3.Research on the relationship between CD10 expression and the invasive breast cancer molecular classifications,to explore whether CD10 as an independent predictor of breast cancer prognosis markers.MethodThis study selected 62 cases of invasive breast cancer,staging II,III of giving neoadjuvant chemotherapy(TEC program is 21 days a cycle,wherein epirubicin:75mg/m~2 d1,21 days for a period;cyclophosphamide:500mg/m~2,d1,21 days for a cycle;docetaxel:75mg/m~2,d1,21 days for a period of 21 days)2-4 cycles,then underwent surgery.Detect the expression of CD10 in Samples among before and after NACT by IHC.And evaluate the effect of NACT by Miller and Payne(M&P)for pathological grading system.We use SPSS 13.0 for statistical analysis.Results1.Among the 62 patients with breast cancer,including 51 cases of invasive ductal carcinoma,11 invasive lobular carcinomas.The expression of CD10 between before NACT and after NACT by IHC shows no significant difference(P>0.05),which means neoadjuvant chemotherapy had no effect on the expression of CD10.2.62 cases of invasive breast cancer after neoadjuvant chemotherapy,there are CR5cases,PR34 cases,SD12 cases,PD11 cases.Miller and Payne(M&P)for pathological grading system:11 cases of grade I,12 cases of grade II,21 cases of grade III,13 cases of grade IV,5 cases of grade V.CD10 expression in neoadjuvant chemotherapy intensity and moderate correlation(contact number of columns is 0.419,P=0.039).3.The invasive breast cancer Luminal A type,Luminal B type,HER-2 overexpr-ession and triple-negative type of CD10 expression are no difference(Pearson chi-square value of 11.210,P=0.082>0.05),thus the CD10 expression and invasive breast molecular cancer classification irrelevant.Conclusions1.CD10 expression was no significant difference in invasive breast cancer before and after neoadjuvant chemotherapy.Neoadjuvant chemotherapy does not affect the expr-ession of CD10.2.The intensity of CD10 expression and the efficacy of neoadjuvant chemotherapy were middle correlated,CD10 negative effect of neoadjuvant chemotherapy is good,the higher the positive rate of CD10 expression,the worse the response to neoadjuvant chemotherapy.We can consider the CD10 as a predictor to evaluate the efficacy of neoadjuvant chemotherapy,in order to develop individualized treatment programs.3.CD10 expression levels of breast cancer independent of molecular subtype,can be used together to predict disease-free survival and recurrence rates in breast cancer patients.